PD-L1 Lung (Atezolizumab), IHC

MDFCPIHC94480 or 94480

Formalin-fixed paraffin-embedded tissue, NSCLC collected in an IHC specimen transport kit

5 unstained charged(+) slides in an IHC specimen transport kit

FFPE: State any other type of fixative used. A pathology report which includes the paraffin block number, and both macroscopic and microscopic evaluation and diagnosis, should be sent with the specimen.

Room temperature

Formalin-fixed paraffin-embedded tissue:
Room temperature: 5 years
Refrigerated: 5 years
Frozen: Unacceptable

Unstained charged(+) slides:
Room temperature: 30 days
Refrigerated: 30 days
Frozen: Unacceptable

Baked or melted slides; previously stained slides; cytospins; tissue types other than lung cancer specimens; cytology cell block; decalcified specimens; fixatives other than formalin; non small cell lung (NSCLC) cancer specimens (primary or metastatic) are the only acceptable tissue type, other tissue types submitted will be rejected

Mon-Fri

3-5 days from receipt

See Laboratory Report

TECENTRIQ is the first FDA-approved anti-PD-L1 cancer immunotherapy which is indicated for the treatment of patients with metastatic non-small cell lung cancer (NSCLC) who have disease progression during or following platinum- containing chemotherapy. Determining a patient's PD-L1 expression level can provide insight into the survival benefit that may be achieved from treatment with TECENTRIQ. PD-L1 expression in ≥50% tumor cells (TC) or ≥10% tumor-infiltrating immune cells (IC) (lymphocytes, macrophages, dendritic cells, and granulocytes) determined by VENTANA PD-L1 (SP-142) Assay/Quest PD-L1 Lung (Atezolizumab) in non-small cell lung cancer tissue may be associated with enhanced overall survival from TECENTRIQ (atezolizumab).